LIDAMIDINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H16N4O
Molecular Weight	220.2709
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CNC(=N)NC(=O)NC1=C(C)C=CC=C1C

InChI

InChIKey=RRHJHSBDJDZUGL-UHFFFAOYSA-N

InChI=1S/C11H16N4O/c1-7-5-4-6-8(2)9(7)14-11(16)15-10(12)13-3/h4-6H,1-3H3,(H4,12,13,14,15,16)

HIDE SMILES / InChI

Molecular Formula	C11H16N4O
Molecular Weight	220.2709
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://onlinelibrary.wiley.com/doi/10.1002/ddr.430070202/abstract | https://www.ncbi.nlm.nih.gov/pubmed/582538 | https://www.ncbi.nlm.nih.gov/pubmed/3404458

Lidamidine, also known as WHR-1142A and Lidaral, is an alpha2-adrenergic receptor agonist that inhibits intestinal secretion, reduces intestinal transit, and inhibits smooth muscle contraction. Lidamidine hydrochloride is used to treat diarrhoea and other gastrointestinal disorders. Lidamidine’s intestinal antisecretory effects are mediated through the activation of peripheral alpha-2 adrenoceptors. Lidamidine crosses the blood brain barrier poorly and is therefore devoid of the centrally mediated alpha-2 effects that have limited the use of other alpha-2 adrenoceptor agonists in the intestinal tract.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor alpha-2 113 Target ID: CHEMBL2095158 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2891549 \| http://en.pharmacodia.com/web/drug/1_7306.html \| http://onlinelibrary.wiley.com/doi/10.1002/ddr.430070202/abstract \|	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Diarrhea 35 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2979258 https://www.ncbi.nlm.nih.gov/pubmed/3940258	Primary		Approved 8429	Lidarral Approved Use Lidamidine Hydrochloride. Lidamidine is an alpha2-adrenergic receptor stimulant used as the hydrochloride for the management of diarrhoea and other gastrointestinal disorders.

PubMed

Title	Date	PubMed
In vivo antimotility and antidiarrheal activity of lidamidine hydrochloride (WHR-1142A), a novel antidiarrheal agent. Comparison with diphenoxylate and loperamide.	1978	582536

Patents

Sample Use Guides

In Vivo Use Guide

Lidamidine HCL (4 mg) or placebo was taken orally t.i.d. with food. Lidamidine decreased the augmented mechanical response to food, reduced rectal sensitivity, and relieved symptoms of patients with irritable bowel syndrome.

Route of Administration: Oral

In Vitro Use Guide

The effects of clonidine and lidamidine on ion transport in the intestine of the rabbit were determined. In the ileum both clonidine (10(-6) M) and lidamidine (10(-3) M) (a) decreased the short circuit current (-1.9 +/- 0.3 and -2.0 +/- 0.4 muEq/h . cm2, respectively) and potential difference; (b) increased net sodium absorption (2.0 +/- 0.6 and 1.8 +/- 0.4 muEq/h . cm2) and chloride absorption (3.4 +/- 0.5 and 3.4 +/- 0.6 muEq/h . cm2); and (c) increased tissue conductance (8.7 +/- 1.7 and 10.0 +/- 1.6 mmho/cm2).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:16:21 GMT 2023` Edited by `admin` on `Fri Dec 15 16:16:21 GMT 2023`
Record UNII	Q8X04W8418
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LIDAMIDINE

Official Name

English

Lidamidine [WHO-DD]

Common Name

English

lidamidine [INN]

Common Name

English

1-(METHYLAMIDINO)-3-(2,6-XYLYL)UREA

Systematic Name

English

UREA, N-(2,6-DIMETHYLPHENYL)-N'-(IMINO(METHYLAMINO)METHYL)-

Systematic Name

English

LIDAMIDINE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C266